- Home
- ACAD vs DYN Comparison
ACAD vs DYN Comparison
Compare ACAD & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- DYN
- Stock Information
- Founded
- ACAD 1993
- DYN 1984
- Country
- ACAD United States
- DYN United States
- Employees
- ACAD N/A
- DYN N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- DYN Medicinal Chemicals and Botanical Products
- Sector
- ACAD Health Care
- DYN Health Care
- Exchange
- ACAD Nasdaq
- DYN Nasdaq
- Market Cap
- ACAD 2.8B
- DYN 2.6B
- IPO Year
- ACAD 2004
- DYN 2020
- Fundamental
- Price
- ACAD $17.57
- DYN $14.13
- Analyst Decision
- ACAD Buy
- DYN Strong Buy
- Analyst Count
- ACAD 19
- DYN 10
- Target Price
- ACAD $26.17
- DYN $50.70
- AVG Volume (30 Days)
- ACAD 4.3M
- DYN 1.8M
- Earning Date
- ACAD 02-25-2025
- DYN 03-04-2025
- Dividend Yield
- ACAD N/A
- DYN N/A
- EPS Growth
- ACAD N/A
- DYN N/A
- EPS
- ACAD 0.78
- DYN N/A
- Revenue
- ACAD $929,236,000.00
- DYN N/A
- Revenue This Year
- ACAD $36.78
- DYN N/A
- Revenue Next Year
- ACAD $8.19
- DYN N/A
- P/E Ratio
- ACAD $22.63
- DYN N/A
- Revenue Growth
- ACAD 47.06
- DYN N/A
- 52 Week Low
- ACAD $14.15
- DYN $14.03
- 52 Week High
- ACAD $29.29
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- ACAD 52.06
- DYN 19.54
- Support Level
- ACAD $16.61
- DYN $14.79
- Resistance Level
- ACAD $18.23
- DYN $15.90
- Average True Range (ATR)
- ACAD 0.74
- DYN 1.55
- MACD
- ACAD -0.05
- DYN -0.82
- Stochastic Oscillator
- ACAD 36.59
- DYN 0.82
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.